1. Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE, McBride A, Rauser L, Hufeisen S, Lee DK.. (2000) 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors., 43 (5): [PMID:10715164] [10.1021/jm990550b] |
2. Glennon RA.. (1987) Central serotonin receptors as targets for drug research., 30 (1): [PMID:3543362] [10.1021/jm00384a001] |
3. Gaillard P, Carrupt PA, Testa B, Schambel P.. (1996) Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models., 39 (1): [PMID:8568799] [10.1021/jm950410b] |
4. Kline TB, Benington F, Morin RD, Beaton JM, Glennon RA, Domelsmith LN, Houk KN, Rozeboom MD.. (1982) Structure-activity relationships for hallucinogenic N,N-dialkyltryptamines: photoelectron spectra and serotonin receptor affinities of methylthio and methylenedioxy derivatives., 25 (11): [PMID:6815326] [10.1021/jm00353a021] |
5. Glennon RA, Naiman NA, Pierson ME, Smith JD, Ismaiel AM, Titeler M, Lyon RA.. (1989) N-(phthalimidoalkyl) derivatives of serotonergic agents: a common interaction at 5-HT1A serotonin binding sites?, 32 (8): [PMID:2754715] [10.1021/jm00128a039] |
6. Glennon RA, Dukat M, el-Bermawy M, Law H, De los Angeles J, Teitler M, King A, Herrick-Davis K.. (1994) Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines., 37 (13): [PMID:8027974] [10.1021/jm00039a004] |
7. Tomaszewski Z, Johnson MP, Huang X, Nichols DE.. (1992) Benzofuran bioisosteres of hallucinogenic tryptamines., 35 (11): [PMID:1534585] [10.1021/jm00089a017] |
8. Tsai Y, Dukat M, Slassi A, MacLean N, Demchyshyn L, Savage JE, Roth BL, Hufesein S, Lee M, Glennon RA.. (2000) N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists., 10 (20): [PMID:11055342] [10.1016/s0960-894x(00)00453-4] |
9. Glennon RA.. (2003) Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7)., 46 (14): [PMID:12825922] [10.1021/jm030030n] |
10. Glennon RA, Hong SS, Bondarev M, Law H, Dukat M, Rakhi S, Power P, Fan E, Kinneau D, Kamboj R, Teitler M, Herrick-Davis K, Smith C.. (1996) Binding of O-alkyl derivatives of serotonin at human 5-HT1D beta receptors., 39 (1): [PMID:8568822] [10.1021/jm950498t] |
11. Macor JE, Fox CB, Johnson C, Koe BK, Lebel LA, Zorn SH.. (1992) 1-(2-Aminoethyl)-3-methyl-8,9-dihydropyrano[3,2-e]indole: a rotationally restricted phenolic analog of the neurotransmitter serotonin and agonist selective for serotonin (5-HT2-type) receptors., 35 (20): [PMID:1433172] [10.1021/jm00098a005] |
12. Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE.. (1999) Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain., 42 (20): [PMID:10514296] [10.1021/jm990325u] |
13. Macor JE, Blake J, Fox CB, Johnson C, Koe BK, Lebel LA, Morrone JM, Ryan K, Schmidt AW, Schulz DW.. (1992) Synthesis and serotonergic pharmacology of the enantiomers of 3-[(N-methylpyrrolidin-2-yl)methyl]-5-methoxy-1H-indole: discovery of stereogenic differentiation in the aminoethyl side chain of the neurotransmitter serotonin., 35 (23): [PMID:1447752] [10.1021/jm00101a032] |
14. Vermeulen ES, Schmidt AW, Sprouse JS, Wikström HV, Grol CJ.. (2003) Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site., 46 (25): [PMID:14640545] [10.1021/jm030826m] |
15. Glennon RA, Jacyno JM, Salley JJ.. (1982) 2,3-dihydro and carbocyclic analogues of tryptamines: interaction with serotonin receptors., 25 (1): [PMID:7086824] [10.1021/jm00343a013] |
16. Glennon RA, Titeler M, Lyon RA, Slusher RM.. (1988) N,N-di-n-propylserotonin: binding at serotonin binding sites and a comparison with 8-hydroxy-2-(di-n-propylamino)tetralin., 31 (4): [PMID:2965244] [10.1021/jm00399a031] |
17. Kline TB, Benington F, Morin RD, Beaton JM.. (1982) Structure-activity relationships in potentially hallucinogenic N,N-dialkyltryptamines substituted in the benzene moiety., 25 (8): [PMID:7120280] [10.1021/jm00350a005] |
18. May JA, Dantanarayana AP, Zinke PW, McLaughlin MA, Sharif NA.. (2006) 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity., 49 (1): [PMID:16392816] [10.1021/jm050663x] |
19. Kolanos R, Dukat M, Roth BL, Glennon RA.. (2006) Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors., 16 (22): [PMID:16945532] [10.1016/j.bmcl.2006.08.068] |
20. Yu L, Ho L, Liao J, Chen C. (1997) Two 5-HT 1A Receptor-Interactive Tryptamine Derivatives from the Unripe Fruit of Evodia rutaecarpa , 60 (11): [10.1021/np960678l] |
21. PubChem BioAssay data set, |
22. PubChem BioAssay data set, |
23. PubChem BioAssay data set, |
24. PubChem BioAssay data set, |
25. PubChem BioAssay data set, |
26. Pullagurla M, Dukat M, Roth BL, Setola V, Glennon RA. (2005) 5-ZATRYPTAMINE ANALOGS AS h5-HT6 SEROTONIN RECEPTOR LIGANDS, 14 (1): [10.1007/s00044-004-0121-8] |
27. Queiroz MM, Queiroz EF, Zeraik ML, Ebrahimi SN, Marcourt L, Cuendet M, Castro-Gamboa I, Hamburger M, da Silva Bolzani V, Wolfender JL.. (2014) Chemical composition of the bark of Tetrapterys mucronata and identification of acetylcholinesterase inhibitory constituents., 77 (3): [PMID:24521095] [10.1021/np401003p] |
28. Glennon RA, Gessner PK, Godse DD, Kline BJ.. (1979) Bufotenine esters., 22 (11): [PMID:533890] [10.1021/jm00197a025] |
29. Glennon RA, Liebowitz SM, Mack EC.. (1978) Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues., 21 (8): [PMID:278843] [10.1021/jm00206a022] |
30. de la Fuente Revenga M, Fernández-Sáez N, Herrera-Arozamena C, Morales-García JA, Alonso-Gil S, Pérez-Castillo A, Caignard DH, Rivara S, Rodríguez-Franco MI.. (2015) Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential., 58 (12): [PMID:26023814] [10.1021/acs.jmedchem.5b00245] |
31. Dunlap LE, Azinfar A, Ly C, Cameron LP, Viswanathan J, Tombari RJ, Myers-Turnbull D, Taylor JC, Grodzki AC, Lein PJ, Kokel D, Olson DE.. (2020) Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies., 63 (3): [PMID:31977208] [10.1021/acs.jmedchem.9b01404] |
32. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |
33. Kargbo RB.. (2021) The Psychedelic Renaissance: Addressing Potential Adverse Effects in a Therapeutic Setting., 12 (12.0): [PMID:34917241] [10.1021/acsmedchemlett.1c00577] |
34. Kargbo RB.. (2022) Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants., 13 (4.0): [PMID:35450349] [10.1021/acsmedchemlett.2c00129] |
35. Unpublished dataset, |
36. International Nonproprietary Names for Pharmaceutical Substances (INN), |